Articles On Imugene (ASX:IMU)

The Zip Co Ltd (ASX: ZIP) share price is avoiding the worst of a brutal sell-off today. Though, the bigger picture potential for this ASX buy now, pay later (BNPL) share could be unflattering. Amid the broad and heavy selling, Zip shares...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The Link Administration Holdings Ltd (ASX: LNK) share price is falling again on Monday. In early trade, the administration services company’s shares are down 11% to $2.93. This means the Link share price has now dropped 33% since this ti...

Arovella Therapeutics (ALA) partners with Imugene (IMU) to conduct a pre-clinical trial to target solid cancers The trial will see Arovella’s CAR19-iNKT cell therapy used in combination with Imugene’s onCARlytics platform to seek and destro...

One of my worst performers in my ASX share portfolio this year has been Newcrest Mining Ltd (ASX: NCM). Newcrest, the largest ASX 200 gold miner on the share market, has had a shocker in recent years. Not only have Newcrest shares suffered...

On Wednesday, the S&P/ASX 200 Index (ASX: XJO) was well and truly out of form and sank deep into the red. The benchmark index dropped 1.6% to 6,700.2 points. Will the market be able to bounce back from this on Friday and end the week...

The S&P/ASX 200 Index (ASX: XJO) waved farewell to eight companies on Monday morning. The benchmark index also welcomed eight others. The shakeup was part of the S&P Dow Jones Indices quarterly rebalance, which seeks to maintain r...

ASX 200 down 1.6% Small caps short 1.3% Real Estate stocks hit ahead of FOMC meet   The benchmark killed Tuesday only to find its very own number was up today. The ASX 200 has spent the session retracing yesterday’s 1.3% gains – driven b...

Highlights: The S&P/ASX 200 closed down on Wednesday (21 September 2022), losing 1.56% to 6,700.20. The benchmark index has lost 1.88% in the last five trading days and is down 7.89% over the last 52 weeks. All eleven sectors ende...

The ASX 200 fell 1.60% to a 2-month low on Wednesday Gold miners, Tech and Real Estate were hit hardest The ASX will be closed on Thursday, but the Fed decision is due at 4am AEST   The ASX 200 gave up yesterday’s gains as it tumbled 1.6%...

The S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is on course to end the day deep in the red. At the time of writing, the benchmark index is down 1.6% to 6,699.2 points. Four ASX shares that are falling more t...

ShareCafeLunch Report: 21 September, 2022 by Paul Sanger   Australian shares have dropped in morning trade, ahead of a US Federal Reserve meeting which is likely to result in another large interest rate hike. At noon, the S&P/ASX 200 is...

Imugene (IMU) doses the first patient in the intravenous cohort of its VAXINIA phase one clinical trialThe trial is evaluating the safety of VAXINIA, a cancer-killing virus being developed by Imugene, in patients with metastatic advanced so...

Telix Pharma releases positive study results for TLX101 Imugene doses first patient in Phase 1 clinical trial Final IPAX-1 study data has confirmed the safety and tolerability profile for TLX101, according to Telix Pharma (ASX:TLX). The s...

The ASX closed 1.6 per cent lower to a two-month low amid jitters about the fallout of the next US rate hike. Imugene, Sayona Mining and Champion Iron lead the losses. Still, Soul Patts and Viva Energy found strong support. 

The S&P/ASX 200 Index (ASX: XJO) rebounded from its recent suffering, driven higher by mining giants on Tuesday. The index closed 1.29% higher at 6,806.40 points today. Mining stocks led the pack today, with the S&P/ASX 200 Materi...

The share market fell to a two-month low as investors braced for another jumbo US rate hike. The S&P/ASX 200 dropped 19 points or 0.28 per cent to 6719.9, its weakest close since July 19. Gains in real estate investment trusts and...

A holiday-shortened trading week got off to a downbeat start as gains in mining and property stocks were outweighed by declines across the wider market. The S&P/ASX 200 reached mid-session six points or 0.1 per cent in the red. The i...

Imugene (IMU) receives the DIR licence required to expand its phase one clinical trial targeting patients with metastatic or advanced solid tumours in AustraliaThe licence, granted by the Australian Government’s Office of the Gene Technolog...

The Imugene Limited (ASX: IMU) share price is shooting higher on Monday morning. At the time of writing, Imugene shares are up 4.54% to 23 cents. What’s driving Imugene shares higher? Investors are bidding up the Imugene share price afte...

Highlights The Australian share market opened in the red. The ASX 200 fell 0.80 points, or 0.015%, to 6,738.30 at the open. The index has lost 3.25% in the past five days. The Australian share market opened in the red...

The Imugene Limited (ASX: IMU) share price finished flat for today, but has been in the red for week. At Friday’s market close, the clinical stage immuno-oncology company’s shares ended at 22 cents a pop. This means the share is down 6.38%...

On Tuesday, cancer immunotherapy developer Imugene [ASX:IMU] announced an $80 million placement to fund its clinical pipeline. The post Imugene Announces $80 Million Placement appeared first on Money Morning Australia.

The share market sealed its longest winning run in six weeks with a fourth day of gains amid expectations tonight’s US consumer price index will confirm inflation has peaked.   The S&P/ASX 200 rallied 45 points or 0.65 per cent. This...

The share market regained 7000 as its longest win run in more than a month entered a fourth day. The S&P/ASX 200 rallied 39 points or 0.56 per cent by mid-session to 7004. On-going rebounds in crude, gold and silver lifted energy...

The Imugene Limited (ASX: IMU) share price has come out of a trading halt today. This comes after the clinical stage immuno-oncology company provided an update in regards to its latest capital raise. At the time of writing, Imugene shares...

The ASX is set for a positive session Wall Street stocks surged again overnight Asian markets to close for Mid-Autumn Festival Another bouyant day of trade on Wall Street has led the local futures market higher, with the ASX 200 September...

Imugene (IMU) taps private investors for $80 million via a share placement to ensure a “long runway” of funds for its existing and future clinical programmesThe company will issue 400 million shares at 20 cents per share to institutional in...

Highlights The Australian share market opened higher on Tuesday. The ASX 200 rose 10.40 points, or 0.15%, to 6,974.90 at the open. The index has gained 2.17% in the past five days. The Australian share market opened hi...

Clinical trials access startup HealthMatch has raised $10 million in Series C. The round was led by the company’s original backer, Folklore Ventures. Paul Bassat’s Square Peg Capital led an $18 million Series B in the Sydney-based startup i...

Imugene (IMU) enters a trading halt ahead of a capital raise to facilitate investment from two new institutional investorsTrading of IMU shares will be paused until Wednesday, September 14, by which time the company should have released fur...

ASX 200 gains 1%  Small Caps index does the same, but then gives it all back ODE wins and NIC MD Justin Werner: Hengjaya joins world’s best nickel resources   The ASX Emerging Companies index (XEC) has given all away its early gains on Mo...

The Imugene Limited (ASX: IMU) share price isn’t going anywhere right now. The stock has been put into a trading halt earlier this morning pending the announcement of a capital raising. The Imugene share price last traded at 22.5 cents....

Highlights The ASX 200 benchmark index closed up today (September 9), gaining 0.66% to 6,894.20 points. Over the last five days, the index has gained 0.96%, but is down 7.39% for the last year to date. Materials was the best performin...

ShareCafeLunch Report: 9 September, 2022 by Paul Sanger   Australian shares are on track to end the week higher after Wall Street made gains overnight. The ASX held a minute’s silence at 11am to mark the death of Queen Elizabeth II. At noon...

The Lithium Power International Ltd (ASX: LPI) share price is immobile today following the ASX’s decision to grant a company-requested trading pause. Before being placed on the back-burner, the Lithium Power share price has been enjoyin...

The Imugene Ltd (ASX: IMU) share price is trading well into the green in early afternoon trade on Thursday. At the time of writing, shares in the immuno-oncology company are swapping hands at 23 cents apiece, 4.55% higher on the day....

The ResApp Health Ltd (ASX: RAP) share price is in the green today as investors digest the latest news on Pfizer’s proposed takeover bid. Shares in the ASX healthcare company are up 0.98%, trading at 21 cents at the time of writing after s...

There’s a new development in the fight against the Zika virus. Invion (ASX:IVX) has just demonstrated that its Photosoft compounds were >99% effective in cell-based assays following the application of light. The study showed that Photoso...

Imugene (IMU) doses the first patient in its nextHERIZON phase two clinical trialThe trial is investigating its HER-Vaxx candidate when combined with other cancer treatments in patients with gastric cancerThe primary goal is to measure safe...

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced that the first patient has been dosed in the nextHERIZON Phase 2 clinical trial.

Highlights The ASX 200 benchmark index closed up today (5 September), gaining 0.34% to end at 6,852.20 points. Over the last five days, the index has lost 1.63% and it has plunged 8.92% over the last 52 weeks. Energy was the best perf...

The ASX finishes higher on Monday Energy / Resource only outperforming sectors  ASX 200 quarterly rebalance sees 8 stocks in and 8 stocks out of the index The ASX ended Monday higher by 0.2% and trimmed last week’s losses despite a weak l...

The share market steadied on the eve of an increase in interest rates as a US market holiday and a rebound in key commodities encouraged buyers. The S&P/ASX 200 bounced 23.5 points or 0.34 per cent from Friday’s five-week low. Gai...

A rebound in resource stocks helped the share market weather weak overseas leads ahead of a likely rate rise tomorrow. The S&P/ASX 200 bounced nine points or 0.12 per cent from Friday’s five-week low.   Gains in the energy and mat...

ShareCafeLunch Report: 5 September, 2022 by Paul Sanger   The ASX moved higher in Monday trading, despite the weaker markets in the US on Friday. At noon, the S&P/ASX 200 is 0.28 per cent or 18.80 points higher at 6847.50. The SPI futur...

Biotechnology company Imugene (IMU) opens two additional cohorts for its phase one metastatic advanced solid tumours (MAST) studyThe company reports its first cohort for the intratumoral (IT) administration of its cancer-killing VAXINIA vir...

Pharmaxis gets ~$5m to collaborate on a Phase 2 study of lead drug, PXS‐4728. Imugene escalates to the next dosage in Phase 1 trial Leading charity, Parkinson’s UK, will provide £2.9m (~$5m) to fund a Phase 2 study of the Pharmaxis (ASX:P...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. In this podcast, Motl...

The Imugene Limited (ASX: IMU) share price is in the red today despite a clinical trial update. Imugene shares are currently trading at 25.75 cents, a 0.96% fall. For perspective, the S&P/ASX 200 Health Care Index (ASX: XHJ) is slidi...